Trial Profile

A Phase I First in Human, Randomized, Double-blind, Placebo- Controlled Study in Healthy Adult Volunteers to Evaluate Safety, Tolerability and Pharmacokinetics of LPX-TI641 After Single and Multiple Oral Doses.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 28 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs LPX TI 641 (Primary)
Indications Demyelinating disorders; Multiple sclerosis; Neuromyelitis optica; Rheumatic disorders
Focus Adverse reactions; First in man
Sponsors LAPIX Therapeutics

20 Nov 2024 positive topline results from its Phase I randomized, double-blind, placebo-controlled single and multiple-ascending dose (SAD and MAD) trial published in the Media Release.
10 Jun 2024 Planned number of patients changed from 48 to 72.
10 Jun 2024 Planned End Date changed from 1 Aug 2024 to 1 Nov 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com